Analyst Rating
based on 1 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 1 analysts offering long term price targets for Jubilant Pharmova Ltd. An average target of ₹889
Source: S&P Global Market Intelligence
Jubilant Pharmova Ltd Share analysis
Jubilant Pharmova Ltd price forecast by 1 analysts
Downside of
High
₹889
Target
₹889.00
Low
₹889
Jubilant Pharmova Ltd target price ₹889, a slight downside of -25.84% compared to current price of ₹1173.7. According to 1 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Jubilant Pharmova Ltd revenue growth forecast
Expected growth rate Q1, FY2026:25.46%
Forecast
Actual
Including amortisation and stock based compensations
Jubilant Pharmova Ltd EPS growth forecast
EPS estimate Q1, FY2026:
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹1,128.5₹1,207.952 Week's Low
52 Week's High
₹318.75₹1,247.15
| Returns % | |
| 1 Month Return | + 32.32 % |
| 3 Month Return | + 63.91 % |
| 1 Year Return | + 173.86 % |
| Market Stats | |
| Previous Close | ₹1,198.70 |
| Open | ₹1,195.75 |
| Volume | 6.47L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹19,095.29Cr |
Key Statistics
| P/E Ratio | 34.34 |
| PEG Ratio | 0.83 |
| Market Cap | ₹19,095.29 Cr |
| P/B Ratio | 3.81 |
| EPS | 4.6 |
| Dividend Yield | 0.88 |
| Sector | Pharmaceuticals |
| ROE | 1.32 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹19,095.29 Cr | 32.86% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| HOLD | ₹29,141.32 Cr | 115.85% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| NA | ₹7,131.04 Cr | 8.69% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹13,121.49 Cr | 37.4% | 0.68 | ₹218 Cr | ₹1,296 Cr | |
| BUY | ₹25,351.51 Cr | 217.69% | 0.55 | ₹258 Cr | ₹1,375 Cr |
Company Information
Share Price: ₹1173.70 per share as on 19 Sep, 2024 04:01 PM
Market Capitalisation: ₹19,095.29Cr as of today
Revenue: ₹1,720.40Cr as on June 2024 (Q2 24)
Net Profit: ₹481.80Cr as on June 2024 (Q2 24)
Listing date: 09 Nov, 1994
Chairperson Name: Shyam S Bhartia
| Organisation | Jubilant Pharmova Ltd |
| Headquarters | Noida |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Jubilant Pharmova Ltd
Jubilant Pharmova Stock Gains Amid Positive Outlook - 16 Sep, 2024
Jubilant Pharmova's stock surged on high volumes, driven by a strong radiopharma pipeline and expanding PET diagnostics. However, risks from US inflation and competition in generics could impact growth.
Jubilant Pharmova Hits New High with Strong Earnings - 14 Sep, 2024
Jubilant Pharmova shares reached a new 52-week high, closing at Rs 1193.80, up 13.89%. The company reported a significant profit increase in Q1 FY25, with a 500% dividend declared. Year-to-date, shares are up 106%.
Jubilant Pharmova Hits Record High After FDA News - 11 Sep, 2024
Jubilant Pharmova's stock surged to an all-time high after its subsidiary received a Voluntary Action Indicated classification from the USFDA. The company also announced plans to acquire Pierre Fabre's R&D center, further boosting investor confidence.
Jubilant Pharmova Shares Surge on Strong Earnings - 10 Sep, 2024
Jubilant Pharmova's shares jumped nearly 9% to a record high of ₹1,038 following impressive quarterly earnings, with a net profit increase of 6410.8% year-on-year. The stock has gained over 38% in two months, bolstered by positive guidance and plans to expand research capabilities through the acquisition of Pierre Fabre's R&D center in France.
Jubilant Pharmova Hits Record High on Strong Earnings - 09 Sep, 2024
Jubilant Pharmova shares surged nearly 9% to a record high of Rs 1,038, driven by strong Q1 earnings with a net profit of Rs 481.8 crore. The company also announced plans to acquire an R&D center in France, enhancing its capabilities in Biologics and ADCs.
Jubilant Pharmova Secures US Grant for Manufacturing - 06 Sep, 2024
Jubilant Pharmova has received a grant from the US government to establish a manufacturing facility in the US, allowing flexibility in production and sales.
Jubilant Pharmova Reports Massive Profit Surge - 26 Aug, 2024
Jubilant Pharmova reported a remarkable 7930% year-on-year increase in net profit to Rs 481.80 crore for Q1 FY24, up from Rs 6 crore. The company's shares have also delivered a staggering 436% return in 2024.
Jubilant Pharmova Hits Three-Year High on Acquisition - 19 Aug, 2024
Jubilant Pharmova's subsidiary, Jubilant Biosys, plans to acquire an 80% stake in Pierre Fabre's R&D Centre for €4.4 million, enhancing its drug discovery capabilities.
Jubilant Biosys Acquires Stake in Pierre Fabre Labs - 18 Aug, 2024
Jubilant Biosys will acquire an 80% stake in Pierre Fabre Labs for €4.4 million over two years, enhancing its drug discovery capabilities. Additionally, Pierre Fabre may engage Jubilant Biosys for services worth €7 million in the first four years.
Insights on Jubilant Pharmova Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 5 quarters, 1.59K Cr → 2.14K Cr (in ₹), with an average increase of 6.9% per quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, JUBLPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -58.6 Cr → 482.1 Cr (in ₹), with an average increase of 112.2% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, JUBLPHARMA stock has moved up by 14.5%
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 19.06% to 19.49% in Jun 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 50.68% of holdings in Jun 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 142.7% return, outperforming this stock by 44.8%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 2.27% to 2.25% in Jun 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 25.90% to 25.18% in Jun 2024 quarter
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 50.68% | 0.00 | |
| Foreign Institutions | 19.49% | 2.26 | |
| Mutual Funds | 2.25% | ||
| Retail Investors | 25.18% | ||
| Others | 2.4% | 14.76 |
Key Indicators
Jubilant Pharmova Ltd Valuation
Jubilant Pharmova Ltd in the last 5 years
Lowest (-195.50x)
December 29, 2023
Today (34.34x)
September 18, 2024
Industry (58.50x)
September 18, 2024
Highest (257.22x)
February 16, 2024
Earnings and Dividends
Jubilant Pharmova Ltd Earnings Results
Jubilant Pharmova Ltd’s net profit jumped 7432.81% since last year same period to ₹482.10Cr in the Q1 2024-2025. On a quarterly growth basis, Jubilant Pharmova Ltd has generated 922.7% jump in its net profits since last 3-months.
Read More about Earnings ResultsJubilant Pharmova Ltd Dividends May,2024
In the quarter ending March 2024, Jubilant Pharmova Ltd has declared dividend of ₹5 - translating a dividend yield of 0.85%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Jubilant Pharmova Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Jubilant Pharmova Ltd shares.
Jubilant Pharmova Ltd (JUBLPHARMA) share price today is ₹1173.7
Jubilant Pharmova Ltd is listed on NSE
Jubilant Pharmova Ltd is listed on BSE
- Today’s highest price of Jubilant Pharmova Ltd is ₹1207.9.
- Today’s lowest price of Jubilant Pharmova Ltd is ₹1128.5.
PE Ratio of Jubilant Pharmova Ltd is 34.34
PE ratio = Jubilant Pharmova Ltd Market price per share / Jubilant Pharmova Ltd Earnings per share
Today’s traded volume of Jubilant Pharmova Ltd(JUBLPHARMA) is 6.47L.
Today’s market capitalisation of Jubilant Pharmova Ltd(JUBLPHARMA) is ₹19095.29Cr.
| Jubilant Pharmova Ltd(JUBLPHARMA | Price |
|---|---|
52 Week High | ₹1247.15 |
52 Week Low | ₹318.75 |
Jubilant Pharmova Ltd(JUBLPHARMA) share price is ₹1173.7. It is down -5.89% from its 52 Week High price of ₹1247.15
Jubilant Pharmova Ltd(JUBLPHARMA) share price is ₹1173.7. It is up 268.22% from its 52 Week Low price of ₹318.75
| Jubilant Pharmova Ltd(JUBLPHARMA | Returns |
|---|---|
1 Day Returns | -25% |
1 Month Returns | 32.32% |
3 Month Returns | 63.91% |
1 Year Returns | 173.86% |